文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

老年心源性休克患者静脉-动脉体外生命支持的死亡预测因素:体外生命支持组织登记分析

Mortality Predictors in Elderly Patients With Cardiogenic Shock on Venoarterial Extracorporeal Life Support. Analysis From the Extracorporeal Life Support Organization Registry.
PubMed 文献 · Crit Care Med · 2021-01-01
一句话结论在≥70岁难治性心源性休克患者中,年龄本身不与死亡率增加相关,静脉-动脉体外膜氧合仍应考虑使用,但气道压力、24小时pH、支持时长和肾脏替代治疗可预测死亡。

该研究分析国际体外生命支持组织登记中1997年1月至2018年12月共2644例≥70岁因难治性心源性休克接受静脉-动脉体外膜氧合的患者,按年龄分为70-74岁、75-79岁和≥80岁三组。总体院内死亡率为68.3%,75-79岁组粗死亡率最高(70.1%),并发症以心血管和出血为主且亚组间无差异。气道压力、体外膜氧合启动后24小时pH、支持时长和肾脏替代治疗可预测较高死亡率。心脏移植受者、经导管主动脉瓣置换术后和肺栓塞患者院内死亡率较低,而冠状动脉旁路移植+瓣膜术后启动体外膜氧合、失代偿性慢性心力衰竭患者死亡率较高,脓毒症患者死亡率接近100%。作者认为尽管死亡率高,但年龄本身不与死亡率增加相关,老年患者仍应考虑静脉-动脉体外膜氧合,若干预测因素可指导适应证和管理。

要点

  • ≥70岁难治性心源性休克患者接受静脉-动脉体外膜氧合后总体院内死亡率为68.3%,75-79岁组粗死亡率最高(70.1%)。
  • 年龄本身不与死亡率增加相关,作者认为即使老年患者,静脉-动脉体外膜氧合仍应考虑使用。
  • 气道压力、体外膜氧合启动后24小时pH、体外膜氧合支持时长和肾脏替代治疗可预测较高死亡率。
  • 心脏移植受者、经导管主动脉瓣置换术后和肺栓塞患者院内死亡率较低;脓毒症患者死亡率接近100%。
  • 外围血管通路是大多数患者采用的接入方式,中位支持时长为3.5天(四分位距1.6-6.1天),≥80岁组为3.9天。

适用人群与场景

  • ≥70岁老年患者,因各种病因导致难治性心源性休克(排除心脏骤停)接受静脉-动脉体外膜氧合。
  • 分析纳入国际体外生命支持组织登记中1997年1月至2018年12月的2644例患者,分为70-74岁(1395例,52.8%)、75-79岁(858例,32.5%)和≥80岁(391例,14.8%)三组。

处置流程与药物剂量

  • 大多数患者采用外围血管通路进行静脉-动脉体外膜氧合。
  • 中位体外膜氧合支持时长为3.5天(四分位距1.6-6.1天),≥80岁组为3.9天(四分位距3.7-4.6天)。
  • 46.7%(1236例)的患者成功脱离体外膜氧合。

研究设计与关键结果

  • 研究类型为国际多中心登记分析,纳入2644例≥70岁难治性心源性休克患者,接受静脉-动脉体外膜氧合,按年龄分为三组。
  • 总体院内死亡率为68.3%,75-79岁组粗死亡率最高(70.1%),并发症以心血管和出血为主,亚组间无显著差异。
  • 气道压力、体外膜氧合启动后24小时pH、体外膜氧合支持时长和肾脏替代治疗可预测较高死亡率。
  • 心脏移植受者、经导管主动脉瓣置换术后和肺栓塞患者院内死亡率较低;冠状动脉旁路移植+瓣膜术后启动体外膜氧合和失代偿性慢性心力衰竭患者死亡率较高;脓毒症患者死亡率接近100%。

证据类型、等级与局限

  • 证据类型为国际多中心登记分析(回顾性队列研究),证据等级未报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于≥70岁难治性心源性休克患者,年龄本身不应作为排除静脉-动脉体外膜氧合的单独依据,因年龄本身不与死亡率增加相关(作者结论)。
  • 气道压力、体外膜氧合启动后24小时pH、支持时长和肾脏替代治疗可预测较高死亡率,可能有助于指导适应证和管理(作者结论)。
  • 脓毒症所致难治性心源性休克患者接受静脉-动脉体外膜氧合后死亡率接近100%,临床决策时需考虑此高风险情况。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Because significantly higher mortality is observed in elderly patients undergoing venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock, decision-making in this setting is challenging. We aimed to elucidate predictors of unfavorable outcomes in these elderly (≥ 70 yr) patients.

DESIGN: Analysis of international worldwide extracorporeal life support organization registry.

SETTING: Refractory cardiogenic shock due to various etiologies (cardiac arrest excluded).

PATIENTS: Elderly patients (≥ 70 yr).

INTERVENTIONS: Venoarterial extracorporeal membrane oxygenation.

MEASUREMENTS AND MAIN RESULTS: Three age groups (70-74, 75-79, ≥80 yr) were in-depth analyzed. Uni- and multivariable analysis were performed. From January 1997 to December 2018, 2,644 patients greater than or equal to 70 years (1,395 [52.8%] 70-74 yr old, 858 [32.5%] 75-79 yr, and 391 [14.8%] ≥ 80 yr old) were submitted to venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock with marked increase in the most recent years. Peripheral access was applied in majority of patients. Median extracorporeal membrane oxygenation support duration was 3.5 days (interquartile range: 1.6-6.1 d), (3.9 d [3.7-4.6 d] in patients ≥ 80 yr) (p < 0.001). Weaning from extracorporeal membrane oxygenation was possible in 1,236 patients (46.7%). Overall in-hospital mortality was estimated at 68.3% with highest crude mortality rates observed in 75-79 years old subgroup (70.1%). Complications were mostly cardiovascular and bleeding, without apparent differences between subgroups. Airway pressures, 24-hour pH after extracorporeal membrane oxygenation start, extracorporeal membrane oxygenation duration, and renal replacement therapy were predictive of higher mortality. In-hospital mortality was lower in heart transplantation recipients, posttranscatheter aortic valve replacement, and pulmonary embolism; conversely, higher mortality followed extracorporeal membrane oxygenation institution after coronary artery bypass + valve and in decompensated chronic heart failure, and nearly 100% mortality followed in extracorporeal membrane oxygenation for sepsis.

CONCLUSIONS: This study confirmed the remarkable increase of venoarterial extracorporeal membrane oxygenation use in elderly affected by refractory cardiogenic shock. Despite in-hospital mortality remains high, venoarterial extracorporeal membrane oxygenation should still be considered in such setting even in elderly patients, since increasing age itself was not linked to increased mortality, whereas several predictors may guide indication and management.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kowalewski M, Zieliński K, Maria Raffa G, et al. Mortality Predictors in Elderly Patients With Cardiogenic Shock on Venoarterial Extracorporeal Life Support. Analysis From the Extracorporeal Life Support Organization Registry. Crit Care Med. 2021. PMID: 33060505. doi:10.1097/CCM.0000000000004695

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。